U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H26FN3O2
Molecular Weight 419.4912
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of E-2012

SMILES

COC1=CC(\C=C2/CCCN([C@@H](C)C3=CC=C(F)C=C3)C2=O)=CC=C1N4C=NC(C)=C4

InChI

InChIKey=PUOAETJYKQITMO-LANLRWRYSA-N
InChI=1S/C25H26FN3O2/c1-17-15-28(16-27-17)23-11-6-19(14-24(23)31-3)13-21-5-4-12-29(25(21)30)18(2)20-7-9-22(26)10-8-20/h6-11,13-16,18H,4-5,12H2,1-3H3/b21-13+/t18-/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H26FN3O2
Molecular Weight 419.4912
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24085193

E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease. E-2012, a new chemical entity discovered by Eisai, has shown some potential in non-clinical studies to reduce the production of beta-amyloid Abeta 40/42 by modulating the function of gamma-secretase without interfering with the Notch-processing.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
81.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
E2012-induced cataract and its predictive biomarkers.
2014 Jan
Patents

Sample Use Guides

Beagle dogs were given a single oral dose of 20 and80 mg/kg E-2012 with a dosing interval of at least 1 week
Route of Administration: Oral
E-2012 was shown to have concentration-dependent inhibitory effects on cholesterol biosynthesis in primary culture of rat hepatocytes and HepG2 cells with IC50 values of 11.0, and 15.1 nmol/l, respectively. Cholesterol synthesis in the rat lens was also reduced by E-2012 at 100 nmol/l and higher.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:42:51 GMT 2023
Edited
by admin
on Sat Dec 16 10:42:51 GMT 2023
Record UNII
3LSD4Y5F0F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
E-2012
Common Name English
(3E)-1-((1S)-1-(4-FLUOROPHENYL)ETHYL)-3-(3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)BENZYLIDENE)PIPERIDIN-2-ONE
Systematic Name English
2-PIPERIDINONE, 1-((1S)-1-(4-FLUOROPHENYL)ETHYL)-3-((3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1-YL)PHENYL)METHYLENE)-, (3E)-
Systematic Name English
Code System Code Type Description
CAS
870843-42-8
Created by admin on Sat Dec 16 10:42:52 GMT 2023 , Edited by admin on Sat Dec 16 10:42:52 GMT 2023
PRIMARY
DRUG BANK
DB05171
Created by admin on Sat Dec 16 10:42:52 GMT 2023 , Edited by admin on Sat Dec 16 10:42:52 GMT 2023
PRIMARY
PUBCHEM
11560787
Created by admin on Sat Dec 16 10:42:52 GMT 2023 , Edited by admin on Sat Dec 16 10:42:52 GMT 2023
PRIMARY
FDA UNII
3LSD4Y5F0F
Created by admin on Sat Dec 16 10:42:52 GMT 2023 , Edited by admin on Sat Dec 16 10:42:52 GMT 2023
PRIMARY
EPA CompTox
DTXSID30468614
Created by admin on Sat Dec 16 10:42:52 GMT 2023 , Edited by admin on Sat Dec 16 10:42:52 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY